Trial Profile

A phase I first-in-human single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial of RLS-1496

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 27 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RLS-1496 (Primary)
Indications Atopic dermatitis; Plaque psoriasis; Psoriasis
Focus Adverse reactions; First in man
Sponsors Rubedo Life Sciences

Most Recent Events

22 May 2025 According to a Rubedo Life Sciences media release, design of the trial was developed with key insights provided by Rubedo's Clinical Advisory Board (CAB) and trial is led by Rubedo Chief Medical Officer and dermatologist Mary Spellman, MD.
22 May 2025 Status changed to recruiting, according to Rubedo Life Sciences media release
22 May 2025 According to a Rubedo Life Sciences media release, announces first patient dosed with LS-1496.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com